alovudine has been researched along with Kidney Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT | 1 |
| Lawrentschuk, N; Poon, AM; Scott, AM | 1 |
1 trial(s) available for alovudine and Kidney Neoplasms
| Article | Year |
|---|---|
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Treatment Outcome | 2015 |
1 other study(ies) available for alovudine and Kidney Neoplasms
| Article | Year |
|---|---|
Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors.
Topics: Carcinoma, Transitional Cell; Dideoxynucleosides; Humans; Kidney; Kidney Diseases, Cystic; Kidney Neoplasms; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals | 2006 |